Drug Search Results
More Filters [+]

Insulin aspart

Alternative Names: insulin aspart, novomix, novomix 30, nn1218, fiasp, novolog, novolog mix 70/30, novolog mix 50/50, ryzodeg 70/30
Latest Update: 2024-08-19
Latest Update Note: Clinical Trial Update

Product Description

Insulin aspart is a short-acting, manmade version of human insulin. Insulin aspart works by replacing the insulin that is normally produced by the body and by helping move sugar from the blood into other body tissues where it is used for energy. It also stops the liver from producing more sugar. (Sourced from: https://medlineplus.gov/druginfo/meds/a605013.html)

Mechanisms of Action: INSR Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Insulin aspart

Countries in Clinic: China, United States

Active Clinical Trial Count: 21

Highest Development Phases

Phase 3: General Diabetes|Healthy Volunteers|Pregnancy Outcomes|Type 1 Diabetes|Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

22011-DM-301

P3

Not yet recruiting

Type 2 Diabetes

2023-12-01

63%

22011-DM-301

P3

Not yet recruiting

Type 2 Diabetes

2023-12-01

63%

In-FI

P3

Completed

Type 2 Diabetes

2023-05-27

API-I004-CL-B

P3

Completed

Healthy Volunteers

2023-01-29

55%

CTR20220854

P1

Completed

Healthy Volunteers|General Diabetes

2022-10-24

Recent News Events